Researchers from South Africa and South Korea are developing a smartphone-based device and application able to “photograph and analyze blood samples in areas far from laboratories to diagnose HIV and even measure the health of [patients’] immune systems,” Agence France-Presse reports. The device, called Smartscope, is a small microscope that clips over a phone’s camera and holds a standard chip with a blood sample, the news service notes, adding the camera then photographs the sample and the application analyzes the photo to produce a CD4 cell count. “The team hopes that trials in clinics may start next year,” according to AFP (8/31).
In a study published on Wednesday in the Lancet, researchers from the Centers for Disease Control and Prevention found that “[a]mong 1,278 patients who were resistant to two or more first-line tuberculosis drugs in Estonia, Latvia, Peru, Philippines, Russia, South Africa, South Korea and Thailand, 43.7 percent showed resistance to at least one second-line drug,” which “suggest[s] the deadly disease may become ‘virtually untreatable,'” according to the study, Bloomberg Businessweek reports (Kitamura/Narayan, 8/29). “In about a fifth of cases, they found resistance to at least one second-line injectable [versus oral] drug,” according to Reuters, which states “[t]his ranged from two percent in the Philippines to 47 percent in Latvia.” Overall, 6.7 percent of patients had extensively drug-resistant TB (XDR-TB), meaning patients are resistant to the first-line drugs isoniazid and rifampicin as well as drugs in the fluoroquinolone antibiotic class and a second-line injectable antibiotic, Reuters adds, noting “[r]ates in South Korea, at 15.2 percent, and Russia at 11.3 percent, were more than twice the WHO’s global estimate of 5.4 percent at that time” (Kelland, 8/30).
As the BRIC countries — Brazil, Russia, India, and China — invest more in innovations in health technologies and other areas, “many are looking to these countries to correct the global health research and development (R&D) imbalance that leaves the poor without needed products such as an improved tuberculosis (TB) vaccine or tests to help diagnose patients in remote rural settings,” David de Ferranti, president of Results for Development Institute (R4D), writes in the Huffington Post Blog. Writing that “India, which has already played such an important role in manufacturing affordable antiretroviral drugs, vaccines, and other essential health commodities for developing countries,” de Ferranti asks whether India “is … ready to play a leading role in health R&D?”
In an article on the U.S. Department of Defense webpage, the American Forces Press Service reports on the first U.S. National Strategy for Biosurveillance, issued by the White House “to quickly detect a range of global health and security hazards.” According to the article, “the Defense Department has a running start in implementing the new plan, a senior defense official said,” and “many of the activities described in the strategy are ongoing at DOD.” “So much of what we’re doing is integrating the efforts and working hard on the overlap between global security and global health, in what [President Barack Obama] refers to as global health security,” said Andrew Weber, assistant secretary of defense for nuclear, chemical and biological defense programs, the news service writes (Pellerin, 8/22).
“Researchers have identified a mysterious new disease that has left scores of people in Asia and some in the United States with AIDS-like symptoms even though they are not infected with HIV,” the Associated Press reports. “This is another kind of acquired immune deficiency that is not inherited and occurs in adults, but doesn’t spread the way AIDS does through a virus, said Dr. Sarah Browne, a scientist at the National Institute of Allergy and Infectious Diseases,” who “helped lead the study with researchers in Thailand and Taiwan where most of the cases have been found since 2004,” according to the news service. “Researchers are calling this new disease an ‘adult-onset’ immunodeficiency syndrome because it develops later in life and they don’t know why or how,” AP writes, adding, “The fact that nearly all the patients so far have been Asian or Asian-born people living elsewhere suggests that genetic factors and something in the environment such as an infection may trigger the disease, researchers conclude” (Marchione, 8/22).
“Each year on August 20, the London School of Hygiene and Tropical Medicine (LSHTM) celebrates [World] Mosquito Day to honor the date in 1897 when British doctor Ronald Ross discovered that female mosquitoes transmit malaria between human beings,” AlertNet reports (Mollins, 8/17). “In 1902, Ross’s discovery earned him the Nobel prize for medicine and laid the foundations for scientists across the world to better understand, beat and treat malaria-carrying mosquitoes,” Sarah Kline, executive director of Malaria No More U.K., writes in the Guardian’s “Poverty Matters” blog.
“Over diagnosis and mistreatment of malaria in central and south Asia may be widespread, leading to the neglect of other serious illnesses, according to a new study from Afghanistan,” published in the British Medical Journal last month, SciDev.Net reports. “Because malaria in this region is rare and mainly caused by a less dangerous form of the disease … overtreatment may actually be worse for public health than it is in Africa or South-East Asia,” the study says, according to the news service. “Researchers assessed the accuracy of malaria diagnoses and treatment for over 2,300 patients with suspected malaria at 22 clinics in northern and eastern Afghanistan” and “found that a large proportion of patients with negative microscopy slides were still being prescribed antimalarial treatment.” “This meant that the real causes of these diseases went untreated,” the news service writes, adding, “The findings contradict a common assumption that there is a greater risk of malaria being missed than over diagnosed in this region of low malaria prevalence, compared with Africa or South-East Asia” (Yusufzai, 8/13).
Diagnostics company Cepheid on Monday signed deals with PEPFAR, USAID, UNITAID, and the Bill & Melinda Gates Foundation to immediately reduce the price of its Xpert MTB/RIF test kit for its GeneXpert tuberculosis (TB) diagnostic system in 145 countries, Reuters reports. “The agreements will see the test sold for $9.98, down from its current price of $16.86 per test,” the news service writes, adding, “Cepheid said the Bill & Melinda Gates Foundation will make an initial payment of $3.5 million to make the test immediately available at the lower price” (Ail, 8/6).
The Ebola virus outbreak that began last month in Uganda is under control, with health agencies having isolated the 176 people who had even slight contact with people who have contracted the virus, Joaquim Saweka, the WHO representative in Uganda, told reporters on Friday in the capital, Kampala, the Associated Press/NPR reports. At least 16 Ugandans have died of the disease in the most recent outbreak, the news service notes. Doctors were slow to recognize the disease because most patients showed atypical symptoms, the AP adds (8/6).
“The first case of cholera has emerged among thousands of people in an impromptu refugee camp in eastern Congo who fled fighting between a new rebel group and government forces backed by U.N. peacekeepers,” according to Medecins Sans Frontieres (MSF), the Associated Press/Washington Post reports (Muhumuza, 8/3). The first case was detected on Friday, and since then at least nine people have died of the disease, MSF said, according to Al Jazeera (8/5).